Trial Profile
hOKT3-gamma-1 (ala-ala) [teplizumab], Sirolimus and Low Dose Tacrolimus Therapy in Type 1 Diabetic Islet Allograft Recipients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Tacrolimus (Primary) ; Teplizumab (Primary)
- Indications Islet cell transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.